A decade of the Clinical Trials Transformation Initiative: What have we accomplished? What have we learned?

被引:10
|
作者
Tenaerts, P. [1 ]
Madre, L. [1 ]
Landray, M. [2 ]
机构
[1] Clin Trials Transformat Initiat, 300 W Morgan St,Suite 800, Durham, NC 27701 USA
[2] Univ Oxford, Oxford, England
关键词
D O I
10.1177/1740774518755053
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The Clinical Trials Transformation Initiative reflects on 10years of working to improve the quality and efficiency of clinical trials. This article highlights many of the Clinical Trials Transformation Initiative's accomplishments and offers examples of the impact that the Clinical Trials Transformation Initiative has had on the clinical trials enterprise. After conducting more than 25 projects and issuing recommendations for specific strategies to improve the design and execution of clinical trials, some common themes and lessons learned have emerged. Lessons include the importance of engaging many stakeholders, advanced planning to address critical issues, discontinuation of non-value added practices, and new opportunities presented by technology. Through its work, the Clinical Trials Transformation Initiative has also derived some operational best practices for conducting collaborative, multi-stakeholder projects covering project selection, project team dynamics and execution, and multi-stakeholder meetings and team discussions. Through these initiatives, the Clinical Trials Transformation Initiative has helped move the needle toward needed change in the clinical trials enterprise that has directly impacted stakeholders and patients alike.
引用
收藏
页码:5 / 12
页数:8
相关论文
共 50 条
  • [1] CLINICAL TRIALS IN SLE: WHAT HAVE WE LEARNED?
    Merrill, J. T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 14 - 14
  • [2] What we have accomplished and what we can achieve
    Morais, A.
    [J]. REVISTA PORTUGUESA DE PNEUMOLOGIA, 2014, 20 (02) : 55 - 56
  • [3] What have we learned from clinical neuroprotective trials?
    Morgenstern, LB
    [J]. NEUROLOGY, 2001, 57 (05) : S45 - S47
  • [4] Stroke trials: What have we learned?
    Madhavan, R
    Jacobs, BS
    Levine, SR
    [J]. NEUROLOGICAL RESEARCH, 2002, 24 : S27 - S32
  • [5] What have we learned from clinical trials on prevention?
    Pellicano, R
    Kerr, PG
    Atkins, RC
    [J]. KIDNEY INTERNATIONAL, 2005, 67 : S101 - S106
  • [6] Amiodarone: What have we learned from clinical trials?
    Naccarelli, GV
    Wolbrette, DL
    Dell'Orfano, JT
    Patel, HM
    Luck, JC
    [J]. CLINICAL CARDIOLOGY, 2000, 23 (02) : 73 - 82
  • [7] Barodontalgia: what have we learned in the past decade?
    Zadik, Yehuda
    [J]. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 2010, 109 (04): : E65 - E69
  • [8] The Stem Cell Decade: What Have We Learned?
    Meslin, Eric M.
    [J]. JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2008, 1 (02) : 95 - 95
  • [9] A decade of dendrimer rheology: What have we learned?
    Dvornic, PR
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U365 - U365
  • [10] The Stem Cell Decade: What Have We Learned?
    Eric M. Meslin
    [J]. Journal of Cardiovascular Translational Research, 2008, 1 : 95 - 95